Curesign is a medical device company aiming to disrupt the way oncologists treat patients with cancer. The companys solution is based on the integration of sensors with advanced signal-processing and big data tools. Curesigns product, which is in the advanced stages of development, is designed to allow clinical teams to tailor a patient-specific treatment for each cancer patient. Curesigns technology has been successfully demonstrated in preclinical studies. Based on the results, the company is currently working on a commercial product for use in many preclinical trials in the field of oncology.